Sequome was founded by Eeshit Dhaval Vaishnav in 2022.

How much funding has Sequome raised?

Sequome has disclosed $10.6M raised across 1 round.

Where is Sequome headquartered?

Sequome is headquartered in South San Francisco, US.

Sequome

South San Francisco, US · Founded 2022 · Delaware corporation

Sequome uses AI to engineer biological sequences for developing therapeutics, based on its sequence-to-function model called Gene Genie. The company has collaborated with large pharmaceutical firms and Google DeepMind in the drug discovery and biotechnology space.

AI & Machine Learning Biotech Deep Tech

Founders & leadership

Sequome was founded in 2022 by Eeshit Dhaval Vaishnav.

Eeshit Dhaval VaishnavFounder

Reported raises · per SEC filings

Form D private placements

$10.6M disclosed across 1 round · 2025

▶$10.6MraisedJul 2025 · 2 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Eeshit Dhaval VaishnavExecutive Officer, Director, Promoter

Offering amount: $11.5M
Amount sold: $10.6M
First sale: Jun 2025
Incorporated: Corporation, Delaware, 2022
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 10

by search overlap

Nucleome16 shared keywordsNucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets. The company builds a data atlas of immune system dysregulation to enable development of genetically-informed therapeutics for inflammatory conditions.

Cellanome14 shared keywordsCellanome develops a live-cell analysis platform using CellCage technology to create controlled microenvironments that enable researchers to observe cell behavior and molecular changes over time. The platform generates structured multimodal data for life sciences researchers and biopharma companies focused on oncology, neuroscience, immunology, and aging research.

Alterome Therapeutics, Inc.14 shared keywordsAlterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic. It focuses on hard-to-drug cancer targets such as mutant KRAS and mutant AKT E17K across malignancies including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancers.

Immunome13 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.

Sensome9 shared keywordsSensome develops a microchip-based tissue-sensing technology that embeds bio-impedance sensors into minimally invasive medical devices to give physicians real-time, patient-specific data during procedures. Its lead product, the Clotild Smart Guidewire System, provides real-time blood clot characterization for acute ischemic stroke treatment, with additional applications in lung cancer biopsy and peripheral vascular intervention.

Myome8 shared keywordsMyOme uses whole genome sequencing and bioinformatics to analyze a single patient sample and produce clinically actionable reports, offering both proactive health tests (such as polygenic risk scores and medication response) and diagnostic tests for rare disease. Its genomic testing serves healthcare providers, patients, employers, and health systems to guide prevention, treatment, and lifestyle decisions.

Noveome Biotherapeutics8 shared keywordsNoveome is a biopharmaceutical company developing ST266, a multi-targeted secretome biologic containing biologically active proteins and factors aimed at neuroprotection, inflammation modulation, and cell recovery. The company is targeting underserved conditions in ophthalmology, neurology, and dermatology.

Freenome7 shared keywordsFreenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases. The company serves healthcare providers and patients seeking preventive cancer screening solutions.

nChroma Bio7 shared keywordsnChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications. The company works with academic founders and institutional investors focused on advancing gene therapy treatments.

Simmunome Inc.7 shared keywordsSimmunome develops AI-powered disease simulation software for drug development, combining mechanistic modeling with machine learning to predict target efficacy and identify patient responders in clinical trials. The SaaS platform serves biotech and pharmaceutical companies across oncology, neurology, and metabolic disease indications.

Companies competing with Sequome for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Sequome do?: Sequome uses AI to engineer biological sequences for developing therapeutics, based on its sequence-to-function model called Gene Genie. The company has collaborated with large pharmaceutical firms and Google DeepMind in the drug discovery and biotechnology space.
Who founded Sequome?: Sequome was founded by Eeshit Dhaval Vaishnav in 2022.
How much funding has Sequome raised?: Sequome has disclosed $10.6M raised across 1 round.
Where is Sequome headquartered?: Sequome is headquartered in South San Francisco, US.